Tackling Europe's 'triple A' challenge: a bold ambition of EU's pharma legislation

Addressing what has been dubbed the ‘triple A’ challenge of access, affordability and availability has been an objective of the European Medicines Agency (EMA) for nearly 30 years, going back to the launch of the centralized procedure in 1995.

As well as an extension of this procedure, efforts over the years since have included the launch of the European Network for Health Technology Assessment (EUnetHTA) Project, the Pharmaceutical Strategy for Europe that was adopted in 2020, and others.

These have helped to chip away at the triple A challenge, and the EMA is already implementing the Regulatory Science Strategy and European Medicines Regulatory Network Strategy to 2025.